The Role Of Rebates In Medicare Part D: So What Exactly Do They Do?
Executive Summary
A US Government Accountability Office Report brings significant new data to the debate over the role of rebates in the Medicare prescription drug program – and makes a complex issue even more complicated.
You may also be interested in...
GAO Report On Part D May Dampen Congressional Enthusiasm For POS Rebates
Legislation redirecting manufacturer rebates on prescription drugs to the point of sale could face an uphill battle following report’s description of the way rebates lower costs in Medicare Part D.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
Medicare Reaffirms Faith In Formulary Review Process Ahead Of Part D Changes
Dramatic transformation in the US Medicare Part D benefit design does not require any changes to CMS’ overall approach to reviewing formulary submissions from private drug plan sponsors, the agency says in its final guidance implementing the design changes for 2025.